MGRX vs MRNA · rev $456.0K vs rev $145.0M
Mangoceuticals, Inc. Common Stock (MGRX) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Mangoceuticals, Inc. Common Stock (MGRX) is a health information services company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
Latest reported MGRX revenue for 2025-12-31 was $456.0K. Net income was -$20.6M. Revenue was down 26.0% from 2024-12-31 to 2025-12-31. MGRX currently screens at market cap $16.3M.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
MGRX currently screens at market cap $16.3M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the MGRX and MRNA stock pages for the full models.
Not investment advice.